Chemical Component Summary

Synonyms9-[(E)-4-[(2S,3R,4R,5S)-3,4-bis(oxidanyl)-5-[[(2S,3S)-3-[(2S,3S)-3-oxidanylbutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methyl-but-2-enoyl]oxynonanoic acid; PSEUDOMONIC ACID
Identifiers9-[(~{E})-4-[(2~{S},3~{R},4~{R},5~{S})-3,4-bis(oxidanyl)-5-[[(2~{S},3~{S})-3-[(2~{S},3~{S})-3-oxidanylbutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methyl-but-2-enoyl]oxynonanoic acid
FormulaC26 H44 O9
Molecular Weight500.622
Isomeric SMILESC[C@H]([C@H]1[C@@H](O1)C[C@H]2CO[C@H]([C@@H]([C@@H]2O)O)C/C(=C/C(=O)OCCCCCCCCC(=O)O)/C)[C@H](C)O

Chemical Details

Formal Charge0
Atom Count79
Chiral Atom Count8
Bond Count80
Aromatic Bond Count0

Drug Info: DrugBank

DrugBank IDDB00410 
  • vet_approved
  • approved
  • investigational
DescriptionMupirocin, formerly termed pseudomonic acid A,[A178531] is a novel antibacterial agent with a unique chemical structure and mode of action apart from other antibiotic agents. Produced by fermentation using the organism _Pseudomonas fluorescens_, mupirocin is a naturally-occurring antibiotic that displays a broad-specturm activity against many gram-positive bacteria and certain gram-negative bacteria _in vitro_.[L10580] It primarily works by inhibiting bacterial protein synthesis. Due to its unique mode of action of inhibiting the activity of bacterial isoleucyl-tRNA synthetase, mupirocin does not demonstrate cross-resistance with other classes of antimicrobial agents, giving it a therapeutic advantage.[L10580] It is available in topical formulations only due to extensive systemic metabolism[A178531] and is used in the treatment of impetigo caused by _Staphylococcus aureus_ and _Streptococcus pyogenes_ and traumatic skin lesions due to secondary skin infections caused by _S. aureus_ and _S. pyogenes_. There is also some clinical evidence that suggests the potential role of mupirocin in eradicating nasal carriage of Staphylococci when administered intranasally.[A178531,A178591] Mupirocin is commonly marketed under the brand name Bactroban.
  • Mupirocinum
  • Mupirocina
  • Pseudomonic acid
  • Pseudomonic acid A
  • 9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3- [(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl] oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid
Brand Names
  • Metronidazole 1% / Mupirocin 2% /
  • Taro-mupirocin
  • Bactroban Nasal Ointment
  • DermacinRx Clorhexacin
  • Lidocaine 2% / Mupirocin 2%
IndicationIndicated for the treatment of impetigo and secondary skin infections, leading to traumatic skin lesions, due to _Staphylococcus aureus_ and _Streptococcus pyogenes_.[L10580]
  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Antibiotics for Topical Use
  • Dermatologicals
  • Enzyme Inhibitors
  • R01AX06
  • D06AX09
CAS number12650-69-0

Drug Targets

NameTarget SequencePharmacological ActionActions
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL719
PubChem 446596
ChEBI CHEBI:94519, CHEBI:7025